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Wandering womb, water and worms:  the history, myths and messy 
immunologic etiology of preeclampsia/eclampsia 
Mark K. Santillan, MD1 
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Introduction: 
“When the womb remains in the upper 
abdomen, the suffocation is similar to that 
caused by the purgative hellebore, with stiff 
breathing and sharp pains in the heart. Some 
women spit up acid saliva, and their mouths are 
full of fluid, and their legs become cold. In such 
cases, if the womb does not leave the upper 
abdomen directly, the women lose their voices, 
and their head and tongue are overcome by 
drowsiness. If you find such women unable to 
speak and with their teeth chattering, insert a 
pessary of wool, twisting it round the shaft of a 
feather in order to get it in as far as possible-dip 
it either in white Egyptian perfume or myrtle or 
bacchar or marjoram. Use a spatula to apply 
black medicine (the kind you use for the head) to 
her nostrils. If this is not available, wipe the 
inside of her nostrils with silphium, or insert a 
feather that you have dipped in vinegar, or 
induce sneezing. If her mouth is closed tight and 
she is unable to speak, make her drink 
castoreum in wine. Dip your finger in seal oil and 
wipe inside her nostrils. Insert a wool pessary, 
until the womb returns, and remove it when the 
symptoms disappear. But if, when you take the 
pessary out, the womb returns to the upper 
abdomen, insert the pessary as you did before, 
and apply beneath her nostrils fumigations of 
ground-up goat or deer horn, to which you have 
added hot ashes, so that they make as much 
smoke as possible, and have her inhale the 
vapour up through her nose as long as she can 
stand it. It is best to use a fumigation of seal oil: 
put the coals in a pot and wrap the woman up-
except for her head. So that as much vapour as 
possible is emitted, drip a little fat on it, and have 
her inhale the vapour. She should keep her 
mouth shut. This is the procedure if the womb 
has fallen upward out of place ...” 
This description of a woman having an 
intrapartum seizure was state of the art 
during the time of Hippocrates in the late 
5th and early 4th centuries BCE.  In this 
passage from his treatise Diseases of 
Women, Hippocrates illustrates a 
woman in the throes of a seizure.  
According to Hippocrates, the treatment 
of such a clinical presentation would 
include applying black medicine, a 
feather, or a pessary with ground up 
goat or deer horn to her nostrils.  
Although such a treatment may seem 
absurd based on today’s understanding 
of preeclampsia/eclampsia, it was based 
on the scientific background of the time.  
Many discoveries have fine-tuned our 
Proceedings in Obstetrics and Gynecology, 2013;3(3):1 
 
 
Wandering womb, water and worms  2 
 
understanding of the complex 
pathogenesis of 
preeclampsia/eclampsia.  Yet, much like 
the ancient Greeks, our understanding 
of this heterogeneous disease is still 
very incomplete.  This paper will 
examine the development of the modern 
conception of preeclampsia/eclampsia, 
its surrounding myths, and the current 
understanding of its etiology. 
A Brief History and Myths of 
Preeclampsia/Eclampsia: 
During the time of Hippocrates, health 
was considered a result of the balance 
of the four major humors: blood, 
phlegm, yellow bile, and black bile.  A 
balance of wet and dry was also 
important to specifically female 
physiology.  It was believed that due to 
the soft, “wetter” nature of female skin, 
women were at higher risk of too much 
moisture leading to an increase in 
humors and consequent sickness.  In 
addition to this fluid imbalance, it was 
also proposed that women got sick due 
to a wandering womb.  In disease 
states, this wandering womb would 
leave the pelvis to seek what it was 
missing.  In the case described above, 
Hippocrates held that the dry uterus 
wandered the body in search of 
moisture.  This gave rise to the 
treatment of fumigations of ground goat 
or deer so the fumigations could provide 
the much needed moisture.  Central to 
this idea of the wandering womb, is that 
in its movement around the female body 
it would cause damage to surrounding 
organs such as the liver, spleen and 
lungs.  Further treatment of female 
maladies was aimed at balancing the 
fluids or humors through blood letting 
and diets.  To maintain the balance, 
Hippocrates held that women needed to 
be pregnant, lactate, and menstruate.1 
Essentially, versions of the humor/ fluid 
balance theory of female disease and 
specifically preeclampsia were 
maintained until the seventeenth 
century.  The term eclampsia first 
appeared in the medical lexicon in 1619 
in Varandaeus’ work on gynecology.  
During the late 1600s and early 1700s, 
Francois Mauriceau was the first to 
describe eclampsia in its modern 
conception.  He held that puerperal 
convulsions were due to decreased 
lochial flow or intrauterine fetal death.  
Even at this time, the Mauriceau 
pathophysiology of convulsions due to 
intrauterine fetal death was a result of 
the foul fluid from the dead fetus.  
Consequently, prevention of 
preeclampsia and eclampsia was still 
through a fluid correction via 
phlebotomy.1 
Despite the continued treatment by 
phlebotomy during the 1800s, the 18th 
and 19th centuries are when the modern 
phenotype of preeclampsia/eclampsia 
began to truly take shape.  In 1849, Dr. 
Williams Tyler Smith published 
Parturition and the Principles and 
Practice of Obstetrics.  In this work, 
Smith held that pregnancy related 
convulsions were due to many causes 
such as mechanical or emotional 
neurologic stimuli, bleeding, 
environmental changes, irritation of the 
gastrointestinal or genitourinary tracts, 
and toxic substances in the body.  
These toxic substances irritate the 
central nervous system causing 
toxemia, a term some still use to 
describe preeclampsia.  As depicted in 
Table 1, the late 18th and the 19th 
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centuries ushered in discoveries that 
truly have shaped the modern definition 
of preeclampsia.1 
Table 1:  The Development of the Modern Definition of Preeclampsia/Eclampsia in 
the 18th and 19th Centuries 
 
Year Author Discovery 
1797 Demanet Connection between edema and eclampsia 
1843 Lever Proteinuria in eclamptics 
1843 Johns Preeclamptic symptoms in late pregnancy described such as headache, 
blurry vision, abdominal pain and edema 
1897 Vaquez and Nobecourt Ecclamptic hypertension 
 
Although the phenotype of 
preeclampsia/eclampsia was taking 
shape during this time, it was not until 
the mid-20th century when the placental 
pathophysiology of preeclampsia began 
to take shape.  It was during the 1960s 
that multiple groups demonstrated that 
placental trophoblast cells were unable 
to invade and convert high resistance 
spiral arteries into high capacity conduit 
vessels thereby causing hypoxia and 
decreased blood flow to the fetal-
placental unit.  As will be discussed later 
in this paper, there are many theories as 
to the modern molecular pathogenesis 
of preeclampsia.  Yet, this placental 
dysfunction lies at the crossroads of all 
these theories. 
Despite modern advances in the 20th 
century, medical science has not fully 
avoided foibles in the investigation of 
the cause of this disease.  In 1983, 2 
reports were published in the American 
Journal of Obstetrics and Gynecology 
suggesting a possible worm-based 
cause for the development of 
preeclampsia.  Aladjem et al. 
reproduced a preeclampsia phenotype 
in pregnant beagles including 
hypertension, hypertensive retinopathy, 
proteinuria, liver dysfunction, glomerular 
endotheliosis, disseminated 
intravascular coagulation, fetal growth 
restriction and fetal death.  They 
achieved this phenotype by 
intraperitoneally inoculating these 
pregnant dogs with placental extracts 
from human placentas that were 
affected by preeclampsia/eclampsia or 
gestational trophoblastic disease.  A key 
finding in these placentas was the 
finding of a worm-like structure termed 
“Hydatoxi lualba”.2  This was observed 
in the first paper from the same group 
by Lueck et al demonstrating these 
worm-like forms in these diseased 
placentas.  In the Lueck paper they 
describe 150 micrometer long larva 
forms with premordial eggs measuring 
7-43 micrometers all of which are found 
in peripheral blood and placental tissue 
of preeclamptics and those with 
gestational trophoblastic disease by 
toluidine blue O staining.  This 
description of these worm-like structures 
were held in comparison to other 
helminths such as hookworms, 
tapeworms, and roundworms.  They 
purported the discovery of a biologically 
active, novel worm species associated 
with the development of these 
placentally-based diseases.3 
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Although an inflammatory, immunologic 
basis for the pathogenesis of 
preeclampsia is at the forefront of all the 
causes of preeclampsia, this apparent 
worm infestation was not a cause of this 
devastating disease.  Subsequent 
articles investigate the origins of these 
worm-like structures. After centrifugation 
of peripheral blood and cord blood and 
passage through small filters, these 
“worms” could not be isolated through 
usual techniques.  It was concluded that 
these worm-like structures were an 
artifact of the toluidine blue O staining 
process.4,5  Therefore, worms are not 
the cause of preeclampsia. 
The story of worms and preeclampsia 
highlights the importance of the rigor 
that must be taken in demonstrating a 
cause for preeclampsia.  As research 
techniques have advanced beyond 
basic histology, the complexity of the 
multiple molecular processes involved in 
the development of preeclampsia make 
its investigation challenging in 
determining the causative from the 
correlative.  Yet, breakthroughs in the 
molecular etiology of preeclampsia have 
expanded our knowledge of its cause 
and are pathways to future predictive 
and therapeutic modalities. 
The Immunologic Etiology of 
Preeclampsia: 
In 1966, T.N. Jeffcoate in the 
Proceedings of the Royal Society of 
Medicine, coined the term “the disease 
of theories” when describing the multiple 
causes of preeclampsia.6  This 
description of preeclampsia still rings 
true as there are multiple molecular 
mechanisms that have been linked to 
the development of preeclampsia 
without a singular unifying, initial 
molecular cause.  Endothelial cell 
dysfunction occur through alterations in 
the usually peripheral vascular 
resistance lowering milieu of pregnancy.  
This altered milieu includes changes in 
relaxin, the endothelin B- nitric oxide 
pathway, and matrix metalloproteinases 
which all have been associated with 
preeclampsia.  Increases in reactive 
oxygen species from multiple sources 
and a dysfunction of normal antioxidant 
enzymes help contribute to the 
endothelial cell dysfunction in 
preeclampsia.  Furthermore, the recent 
elaboration of dysregulated 
angiogenesis and the role of soluble 
vascular endothelial growth factor 
receptor in preeclampsia has placed a 
new emphasis on the vascular etiology 
of preeclampsia.  Despite these multiple 
mechanisms, placental dysfunction 
remains at the core of preeclampsia.7  
Yet, how does the abnormal 
differentiation and invasion of placental 
trophoblasts and decreased flow in the 
placenta initiate? 
There is much data to support that 
preeclampsia may be initiated by an 
immune, rejection-like response to the 
feto-placental unit.  Among these 
observations is the finding that 
multiparous women who conceive by 
the same partner are at lower risk for 
developing preeclampsia.8-10   Because 
different paternity is associated with an 
increased risk to that of primiparity,11  
this finding suggests that a tolerance to 
the antigen develops as a consequence 
of a prior pregnancy.  This antigen is the 
paternal contribution to the fetus.  In 
cases of in vitro fertilization in which the 
male was functionally aspermic, and 
therefore the mothers have never had 
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exposure to the “antigen,” a three-fold 
increase in the incidence of 
preeclampsia was observed when 
women in this cohort were implanted 
with embryos fertilized with the 
surgically removed sperm of their 
partners.12  In cases in which donor 
sperm or oocytes are used and there is 
no protection from self-antigens, there is 
also a significantly increased rate of 
preeclampsia.13,14  Although somewhat 
controversial, lower rates of 
preeclampsia have been found by some 
groups in immunocompromised HIV+ 
women.15 These rates approach the 
expected rate when women are treated 
with triple antiretroviral therapy.16    
Unfortunately, defining the role of 
immune system mechanisms 
responsible in preeclampsia has proven 
elusive because of the many 
components involved. One common-
held theory is that an immune system 
response results in damage to the 
endothelial cells of the microvascular 
system resulting in the multiorgan 
phenotype of preeclampsia.17 This 
endothelial cell damage may also 
originate from endothelial cells 
themselves.  Recent cell culture data 
have demonstrated that endothelial cells 
from nonplacental origins can release 
IL-6, secondary to the phagocytosis of 
necrotic trophoblasts, which can cause 
further endothelial cell activation.  These 
data suggest how endothelial cell 
phagocytosis of necrotic trophoblasts at 
a distant site, such as pulmonary 
capillaries, may cause downstream 
activation of endothelial cells at the local 
and placental level.18  This damage may 
occur as a consequence of exposure of 
the vessels to other cytokines causing 
an inflammatory response or triggering 
apoptosis.  
What triggers the immune system 
response?  What factors damage the 
vessels?  Are multiple pathways 
involved?  These questions are the 
research interests of many labs.  The 
answers will be critical to designing 
drugs to specifically target the immune 
triggers of preeclampsia without 
disabling the entire immune system. 
Among these studies are animal models 
that mimic preeclampsia.  In a mouse 
model established by Zenclussen et 
al.,19 Zenclussen and colleagues 
transferred activated Th1-like cells into 
pregnant mice causing the development 
of preeclamptic symptoms such as 
elevated blood pressure and proteinuria.  
Notably, these findings only developed 
when cells were transferred into 
pregnant mice.  There was no 
hypertension and elevated proteinuria in 
non-pregnant mice.   
One immune system factor that appears 
to be involved in the etiology of 
preeclampsia is indoleamine 2, 3-
dioxygenase (IDO).  IDO is an enzyme 
involved in the degradation of L-
tryptophan, an essential amino acid.  
Depleting T cells of tryptophan inhibits 
their expansion due to an arrest in the 
cell cycle at the G1 phase.20-22 In mice, 
a maternal T-cell reaction against 
paternal antigens was induced when 
IDO was pharmacologically inhibited23 
and fetal rejection occurred 24 indicating 
that IDO may be critical for tolerance of 
the fetus.  The mean number and the 
developmental status of the syngeneic 
embryos were not affected. In contrast, 
allogeneic concepti in IDO inhibitor 
treated dams showed increased 
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hemorrhage, inflammation, and 
degeneration with the death of all 
allogenic concepti by 9.5 days post 
conception. They hypothesize that with 
the interruption of tryptophan catabolism 
by the addition of the IDO inhibitor, T-
cell mediated destruction of paternal 
antigen possibly leads to the rejection of 
the allogeneic fetuses.  Using semi-
quantitative immunohistochemistry, 
Santoso et al.,25 demonstrated that 
significantly less IDO was expressed in 
placentae of term preeclamptic women 
than in control placentae.  IDO staining 
was present in the endothelial cells of 
most capillaries and some arteries of the 
villi in all placentae.  In addition to its 
role in suppressing CD8+ T cells, IDO 
also reduces oxygen free radicals in the 
placenta by utilizing it to cleave L-
tryptophan to form formylkynurenine.  
The reduced levels of IDO in 
preeclamptics may prove to be one of 
the key links between the immune 
response and oxidative damage of 
preeclampsia.   
Other studies have examined more 
global indicators of imbalances in the 
immune system during preeclampsia.  
Jonsson et al.26 found that women with 
preeclampsia had decreased levels of 
spontaneous interleukin (IL)-5 secretion.  
Interestingly, IL-10 secretion in 
response to paternal antigens was 
significantly decreased in women with 
preeclampsia.  IL-10 has potent anti-
inflammatory effects.  In addition, 
decreased numbers of basophil 
granulocytes were found in 
preeclamptics.  The decreased 
secretion of IL-5 and basophils indicate 
a decrease in systemic T helper type 2 
(Th2)-like responses.  Some have 
hypothesized that there is a Th2 shift in 
normal pregnancies because of the 
strong humoral response.27  A Th1 
response, including the presence of 
cytokines such as IL-2, interferon-
gamma (IFN-gamma), and tumor 
necrosis factor-alpha (TNF-alpha) leads 
to the destruction of trophoblast in vitro 
and the loss of pups in pregnant mice.19  
In normotensive pregnant women, 
stimulated peripheral blood 
mononuclear cells (PBMC) produce 
predominantly Th2 cytokines (IL-4, IL-
10); whereas, Th1 cytokines (IFN-
gamma) are predominantly produced 
from women experiencing 
preeclampsia.28  The presence of a Th1 
phenotype may be important in the 
development of preeclampsia. 
Preeclampsia has also been associated 
with changes in the levels of other 
inflammatory cytokines in serum.  Luppi 
et al., investigated plasma levels of IL-6 
as a marker of leukocyte activation.29 
They found significantly increased levels 
of IL-6 in preeclamptic women.  
Suggestive of a role in the endothelial 
dysfunction of preeclampsia, chronic 
infusion of IL-6 was found to affect the 
contraction and relaxation of systemic 
vessels in pregnant rats.30,31 Consistent 
with the increase in IL-6, they found 
increased nuclear translocation of 
nuclear factor kappa-B (NF-κB).  The 
strongly conserved IL-6 promoter 
sequence contains consensus binding 
sites for NF-κB.32 Identification of 
immune system signals and their 
pathways will provide targets for 
therapeutic intervention in preeclampsia.  
The evidence of increased immune 
system signaling in response to the 
allogenic fetus begs the question: what 
serves as the initial antigen?  Fetal 
trophoblast cells are a likely 
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immunogen.  These cells lack HLA 
expression preventing them from being 
recognized by maternal CD8+ T cells; 
however, they are susceptible to lysis by 
natural killer (NK) cells.33  The 
replenishment of the syncytiotrophoblast 
also causes the release of fetal debris 
into the maternal circulation.34  In vitro 
studies have found that interactions 
between vesicles from 
syncytiotrophoblasts and human 
umbilical endothelial cells results in 
neutrophil activation.35,36  Furthermore, 
these microparticles are able to 
stimulate primed peripheral blood 
mononuclear cells to produce cytokines 
including IFN-gamma and TNF-alpha, 
which are part of Th1 response.37  
Functional differences between the 
syncytiotrophoblasts microparticles 
released in normotensive and 
preeclamptic pregnancies have not 
been delineated.38 Other fetal material, 
such as RNA, DNA, or other cell types 
can also be found in the maternal 
circulation.39-42  The number of fetal 
erythrocytes in the maternal circulation 
has been found to be elevated in 
preeclamptic women versus 
normotensive pregnant women.43,44  The 
concentration of fetal material may be 
significant to whether the maternal 
immune system tolerates the semi-
allogeneic fetus or initiates a strong 
response against the fetus. 
Groups have also investigated an 
increase of antibodies in preeclamptic 
women that is not found in women with 
normal pregnancies.  Autoantibodies 
against angiotensin receptor-1 (AT1) in 
the IgG fraction of sera from 
preeclamptic women will induce 
preeclamptic symptoms in pregnant 
mice. These effects were not seen using 
samples from normotensive women. 
The AT1 autoantibodies induce excess 
activation of the AT1 receptor which can 
cause hypertension through the 
interaction of the receptor with its ligand 
angiotensin II, a known mediator of 
elevated blood pressure.  Blocking the 
AT1 receptor reduced the effects in 
mice.  The maternal antibodies that 
activate AT1 may mediate some of the 
cellular changes observed during 
preeclampsia.45 Thway et al. examined 
the ability of IgG from 16 severely 
preeclamptic patients to activate AT1 
receptors and to increase free 
intracellular calcium.46  All of these 
samples activated the receptors and 
increased intracellular calcium in more 
than 50% of Chinese hamster ovary 
(CHO) cells.  Immunoglobulin G (IgG) 
from normotensive pregnant women 
caused an activation of the AT1 receptor 
in less than 20% of CHO cells.  When 
intracellular calcium mobilization 
occurred in the CHO cells exposed to 
IgG from normotensive women (in 4 of 
14 samples), it was not mediated 
through AT1 receptor activation.  
Increased calcium can affect gene 
expression, platelet activation, and 
vasoconstriction.  However, it is unlikely 
that these antibodies are the initial 
causative agent for preeclampsia as 
they have also been found in 
normotensive pregnant women without 
preeclampsia.47 Nevertheless, these 
antibodies affect vasoconstriction and 
pharmacologic inhibition of AT1 
antibodies may aid in the treatment of 
preeclampsia.     
It has also been hypothesized that the 
immune mediated preeclamptic 
pathophysiology is triggered by an 
extra-fetal source.  Some groups have 
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suggested that infection may play a role 
in the development of pre-eclampsia.  A 
recent systematic review and meta-
analysis found an increased risk of 
preeclampsia in pregnant women with a 
urinary tract infection and periodontal 
disease.48  Our own data demonstrate 
no significant difference between the 
overall intrapartum infection rates of 
control and preeclamptic parturients.  
However, we did identify significant 
differences when patients were stratified 
by soluble Heat Shock Protein 60 (s-
HSP60) protein and antibody status.   
Heat Shock Protein 60 is a chaperone 
protein that is known to stimulate 
inflammatory and cytokine pathways in 
response to infectious stimuli.  A higher 
intrapartum infection rate in 
preeclamptics versus controls who were 
positive for s-HSP60 protein and s-anti-
HSP60 antibody.  In addition, 
preeclamptic mothers who have sera 
positive for s-HSP60 have a significantly 
higher rate of intrapartum infection in 
comparison to those in their 
preeclamptic cohort who are sera 
negative.  Further, preeclamptic mothers 
who have sera positive for both s-
HSP60 and s-anti-HSP60 antibody also 
have a significantly higher rate of 
intrapartum infection in comparison to 
other preeclamptics.  This relationship is 
not observed in preeclamptic mothers 
who are sera positive for s-anti-HSP60 
antibody alone.49  These types of 
differences in inflammatory and cytokine 
immunology underscore the importance 
of immunology in the pathogenesis of 
preeclampsia. 
In order to better understand how the 
immune system affects pregnancy 
outcomes, it is important to understand 
the interface between mother and fetus.  
During implantation and placentation, 
the decidua is comprised of almost 40% 
immune cells.  Of these, NK cells are 
most abundant; they represent 
approximately 70% of the immune 
cells.50  These NK cells vary from the 
majority of peripheral blood cells in that 
their phenotype is cytokine producing 
and not cytotoxic.51  Hanna et al. 
demonstrate that decidual NK cells, but 
not peripheral blood-derived NK cells 
can regulate trophoblast invasion 
through the production of IL-8 and 
interferon-inducible protein 10 (IP-10) 
chemokines.  In addition, the decidual 
NK cells secrete several angiogenic 
factors, such as vascular endothelial 
growth factor and placental growth 
factor, and induce vascular growth in the 
decidua. Both the activating and 
inhibitory receptors of the NK cells and 
their ligands are important in 
establishing proper invasion and 
vascularization of the placenta.  The 
ligands to the NK receptors may be 
provided by maternal stromal cells and 
trophoblast cells.  In normal, healthy 
pregnancies decidual NK cells may be a 
key immune system factor in regulating 
placental development.  Further studies 
of NK cells in preeclamptic women will 
be necessary to elucidate how these 
cells are different and to develop 
potential therapies to restore their 
beneficial function in pregnancy. 
Conclusion: 
The understanding of the underpinnings 
of preeclampsia has undergone steady 
change throughout history.  From a 
wandering uterus, the unbalance of 
humors, worms to the current molecular 
theories on the cause of preeclampsia, 
each step in understanding must be 
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made with careful consideration of what 
is associated versus what is truly 
causative.  It is increasingly evident that 
preeclampsia/eclampsia is a disease 
process that is heterogenous in nature.  
Moving forward, the challenge to 
researchers is to find novel predictive, 
therapeutic, and possibly curative 
targets that will address either the root 
cause of preeclampsia or the multitude 
of complex molecular processes 
involved in its development.  Without 
this approach, clinicians will be left with 
a limited treatment arsenal in battling 
this “disease of theories.” 
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